Ascendis Pharma Achieves 86% Response Rate in Phase 3 TransCon PTH Trial at Week 182

Three and a half years of continuous Phase 3 data from Ascendis Pharma now place palopegteriparatide (TransCon PTH) among the most longitudinally characterized prodrug conjugate biologics in endocrinology, with manufacturing and quality control implications that extend well beyond the hypoparathyroidism indication itself.

The completed PaTHway Trial enrolled adults with hypoparathyroidism and ran through Week 182, with 89% of patients completing the full duration. At that endpoint, 86% met the multi-component responder definition: serum calcium within normal range, no active vitamin D, and calcium supplementation at or below 600 mg/day. All patients achieved independence from calcitriol or alfacalcidol. Mean eGFR reached 80.2 mL/min/1.73 m² at Week 182, reflecting an 11.0 mL/min/1.73 m² increase from baseline that stabilized after Week 38 and held against the expected age-related decline.

For QA directors and regulatory leads tracking biologics platforms, the sustained multi-organ profile across CNS, kidney, small intestine, and bone introduces a demanding comparability benchmark. Any post-approval manufacturing change, process scale, excipient source, conjugation yield, will need to demonstrate that the prodrug release kinetics and systemic PTH replication remain within the validated range established over this 182-week dataset. That is a tighter specification corridor than most small-molecule programs carry into lifecycle management.

Bone mineral density Z-scores, normalized from elevated baseline levels by Week 26, remained above zero through Week 182. Mean 24-hour urine calcium normalized within 26 weeks and held stable. Patient-reported outcomes on both the HPES and SF-36 instruments showed rapid and sustained improvement across all subscales. No new safety signals emerged, and no discontinuations were attributed to treatment-emergent adverse events, which were predominantly mild or moderate.

The TransCon platform's mechanism, sustained, steady-state PTH delivery via a prodrug conjugate, means that batch-to-batch consistency in conjugation chemistry and release-rate profiling will carry direct clinical relevance under ICH Q10 and 21 CFR Part 211 frameworks. Regulators reviewing any supplemental application or label expansion will have access to a 182-week comparator dataset, raising the evidentiary bar for any manufacturing variation that could alter pharmacokinetic behavior.

The 89% trial completion rate at 3.5 years also signals a low discontinuation burden, a variable that supply-chain planners will need to factor into long-term demand forecasting as the program moves toward potential geographic label expansions.

The 182-week dataset now serves as the primary reference standard against which any future process changes, formulation updates, or biosimilar development programs for palopegteriparatide will be measured.

Source: Ascendis Pharma A/S via GlobeNewswire, June 13, 2026.